Lilly announces top-line results of Solanezumab phase 3 clinical trial

By Web DeskIslamabad

Indianapolis: Eli Lilly and Company (NYSE: LLY) today announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer’s disease (AD).

Patients treated …